Strategic policy decisions are being made about e-cigarettes, based on the plausibility of their greater safety, rather than on essential scientific evidence which would permit a proper risk assessment. If e-cigarettes are really ‘safer’, then their use should be recommended, but only after an intelligent analysis of their risk to human health, based on integrated in silico, in vitro and clinical studies for both scientific and logistical reasons
Get full access to this article
View all access options for this article.
References
1.
WildeO. (1892). A quotation from Lady Windermere's Fan, a play first performed in 1892 and first published in written form in 1893.
2.
CombesR.D. & BallsM. (2015). A critical assessment of the scientific basis, and implementation, of regulations for the safety assessment and marketing of innovative tobacco-related products. ATLA43, 251–290.
HengstlerJ.G., BogdanffyM.S., BoltH.M. & OeschF. (2002). Challenging dogma: Thresholds for genotoxic carcinogens? The case of vinyl acetate. Annual Reviews of Pharmacology43, 485–520.
9.
ChengT. (2014). Chemical evaluation of electronic cigarettes. Tobacco Control23, Suppl. ii, 11–17.
KimH.J. & ShinH.S. (2013). Determination of tobacco-specific nitrosamines in replacement liquids of electronic cigarettes by liquid chromatography–tandem mass spectrometry. Journal of Chromatography A1291, 48–55.
12.
AkopyanG. & BonavidaB. (2006). Understanding tobacco smoke carcinogen NNK and lung tumorigenesis. International Journal of Oncology29, 745–752.
13.
NeubergerM. (2015). The electronic cigarette: A wolf in sheep's clothing. Wiener Klinische Wochenschrift, Central European Journal of Medicine, doi: 10.1007/s00508-015-0753-3. Available at: http://www.forte.or.at/download.php?id=1725 (Accessed 06.11.15).
14.
CochraneS.A., ArtsJ.H.E., EhnesC., HindleS., HeliM., HollnagelS.H.M., PooleA.SutoH. & KimberI. (2015). Thresholds in chemical respiratory sensitisation. Toxicology333, 179–194.
15.
MegarajV., ZhouX., XieF., LiuZ., YangW. & DingX. (2014). Role of CYP2A13 in the bioactivation and lung tumorigenicity of the tobacco-specific lung procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone: In vivo studies using a CYP2A13-humanised mouse model. Carcinogenesis35, 131–137.
16.
FarsalinosK.E., & PolosaR. (2014). Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: A systematic review. Therapeutic Advances in Drug Safety5, 67–86.
NuttD.J., PhillipsL.D., BalfourD., CurranH.V., DockrellJ.M., FouldsJ., FagerstromK., LetlapeK., MiltonA., PolosaR., RamseyJ. & SweanorD. (2014). Estimating the harms of nicotine-containing products using the MCDA approach. European Addiction Research20, 218–225.
19.
KujawskiE. (2002). Multi-criteria decision analysis: Limitations, pitfalls, and practical difficulties, 9pp. Berkeley, CA, USA: eScholarship, University of California. Available at: http://escholarship.org/uc/item/0cp6j7sj (Accessed 07.11.15).
20.
BroseL.S., BrownJ., HitchmanS.C. & McNeillA. (2015). Perceived relative harm of electronic cigarettes over time and impact on subsequent use. A survey with 1-year and 2-year follow-ups. Drug & Alcohol Dependence157, 106–111.
21.
BullenC., HoweC., LaugesenM., McRobbieH., ParagV., WillimanJ. & WalkerN. (2013). Electronic cigarettes for smoking cessation: A randomised controlled trial. The Lancet382, 1629–1637.
22.
McKeeM. & CapewellS. (2015). Evidence about electronic cigarettes: A foundation built on rock or sand?BMJ351, h4863.
23.
KirbyT. (2015). E-cigarettes declared 95% less harmful than tobacco by UK health body. The Lancet Respiratory Medicine3, 750–751.
PisingerC. & DøssingM. (2014). A systematic review of health effects of electronic cigarettes. Preventive Medicine69, 248–260.
28.
RowellT.R. & TarranR.A. (2015). Will chronic eCigarette use cause lung disease? American Journal of Physiology — Lung Cellular & Molecular Physiology, doi: 10.1152/ajplung.00272.2015. [E-pub ahead of print.]
29.
UngerJ.B. (2015). E-Cigarettes: Introducing new complexities and controversies to the field of nicotine and tobacco research. Nicotine & Tobacco Research17, 1185–1186.
30.
EtterJ-F., BullenC., FlourisA.D., LaugesenM. & EissenbergT. (2011). Electronic nicotine delivery systems: A research agenda. Tobacco Control20, 243–248.
31.
MisraM., LeveretteR.D., CooperB.T., BennettM.B. & BrownS.E. (2014). Comparative in vitro toxicity profile of electronic and tobacco cigarettes, smokeless tobacco and nicotine replacement therapy products: E-liquids, extracts and collected aerosols. International Journal of Environmental Research & Public Health11, 11, 325–11, 347.
32.
NeilsonL., MankusC., ThorneD., JacksonG., DeBayJ. & MeredithC. (2015). Development of an in vitro cytotoxicity model for aerosol exposure using 3D reconstructed human airway tissue; application for assessment of e-cigarette aerosol. Toxicology in Vitro29, 1952–1962.
SancilioS., GalloriniM., CataldiA. & di GiacomoV. (2015). Cytotoxicity and apoptosis induction by e-cigarette fluids in human gingival fibroblasts. Clinical Oral Investigations, 2015 Aug 4. [E-pub ahead of print.]
35.
CaponnettoP., CampagnaD., PapaleG., RussoC. & PolosaR. (2012). The emerging phenomenon of electronic cigarettes. Expert Review of Respiratory Medicine6, 63-74.
36.
VansickelA.R., CobbC.O., WeaverM.F. & EissenbergT.E. (2010). A clinical laboratory model for evaluating the acute effects of electronic “cigarettes”: Nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiology, Biomarkers & Prevention19, 1945.
37.
PalamidasA., GennimataS.A., KaltsakasG., TsikrikaS., VakaliS., GratziouC. & KoulourisN. (2014). Acute effect of an e-cigarette with and without nicotine on lung function. Tobacco Induced Diseases12, Suppl. 1, A34.
FlaccoM.E., FioreM., La VecchiaC., MarzuilloC., GualanoM.R., LiguoriG., CicoliniG., CapassoL., BocciaS., SiliquiniR., RicciardiW., VillariP. & ManzoliL. (2015). Electronic cigarettes: Efficacy and safety at 12 months: Cohort study. European Journal of Public Health25, Suppl. 3, 254.
40.
BrandonT.H., GoniewiczM.L., HannaN.H., HatsukamiD.K., HerbstR.S., HobinJ.A., OstroffJ.S., ShieldsP.G., TollB.A., TyneC.A., ViswanathK. & WarrenG.W. (2015). Electronic nicotine delivery systems: A policy statement from the American Association for Cancer Research and the American Society of Oncology. Journal of Clinical Oncology33, 952–963.
CombesR., BallsM., IllingP., BhogalN., DaleJ., DuvéG., FeronV., GrindonC., GüldenM., LoizouG., PristonR. & WestmorelandC. (2006). Possibilities for a new approach to chemicals risk assessment. The Report of a FRAME Workshop. ATLA34, 621–649.
43.
CombesR.D. (1997). Defining a ‘threshold of regulation’ the ultimate alternative for safety assessment?ATLA25, 187–191.
44.
SepanovI., CarmellaS.G., HanS., PintoA., StrasserA.A., LermanC. & HechtS.S. (2009). Evidence for endogenous formation of N′-nitrosonornicotine in some long-term nicotine patch users. Nicotine & Tobacco Research11, 99–105.
45.
HahnJ., MonakhovaY.B., HengenJ., KohlHimmelseherM., SchusslerJ., HahnH., KuballaT. & LachenmeierD.W. (2014). Electronic cigarettes: Overview of chemical composition and exposure estimation. Tobacco Induced Diseases12, 23.
